DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Hilton Lac-Leamy

2019 年 11 月 05 日 7:30 上午 - 2019 年 11 月 06 日 3:15 下午

3 Boulevard du Casino, Gatineau, QC J8Y 6X4, Canada

DIA Annual Canadian Meeting

概览

The DIA Annual Canadian Meeting will deliver a comprehensive overview of the current bio-pharma and device landscape in Canada, while sharing insights into Canada’s broader role in global healthcare product development. From policy updates and priorities shared directly from Health Canada, to sessions on international work sharing and partnerships to key regulatory and clinical considerations for drugs and devices, you will have the exclusive opportunity to address the current issues and opportunities in Canada and across the globe.

Bringing together key stakeholders from the drug/device and Patient Self Care industries, regulatory agencies, and academia, this meeting will discuss and analyze the relevant challenges and opportunities for professionals working in the field in Canada.


Need approval in order to attend?

Download and fill out our Justification Letter to demonstrate to your supervisor why this is a must-attend event.

Check out our 2019 Program!


Why Attend?


Featured

Want to learn more about DIA Annual Canadian Meeting? You've come to the right site!

Continuing Education

Highlights & Features

谁应该参加?

Professionals in pharmaceutical and device industries, regulatory agencies, and academia involved in:

  • Clinical data management/eClinical
  • Comparative effectiveness/health technology assessment
  • Clinical safety/pharmacovigilance
  • Clinical research
  • Document management/eSubmissions
  • Medical communications
  • Outsourcing
  • Project management
  • Public policy/law/corporate compliance
  • Quality assurance control
  • Regulatory affairs
  • Research and development
  • Statistics

学习目标

At the end of this session, participants should be able to:
  • Describe the current and evolving regulatory environment in Canada
  • Summarize current methods used in clinical trials, patient engagement, and improving market access
  • Discuss approaches on international harmonization, work sharing, and implementation of current guidelines
  • Review the various levels of transparency needed to maintain compliance in pre- and post-market activities

项目委员会

  • Marc  Poitras, PhD, MBA
    Marc Poitras, PhD, MBA Scientific Manager, Marketed Pharmaceuticals and Medical Devices Bureau
    Health Canada, Canada
  • Lisa  Chartrand
    Lisa Chartrand Director, Regulatory Strategy and Policy
    Hoffmann-La Roche Limited, Canada
  • Loretta  Del Bosco
    Loretta Del Bosco Director, Regulatory Affairs Quality Assurance Operations
    AbbVie Corporation, Canada
  • Fiona M Frappier, PhD
    Fiona M Frappier, PhD Senior Policy Analyst
    Health Canada, Canada
  • Lorella  Garofalo, PhD
    Lorella Garofalo, PhD Head of Regulatory Sciences
    Pfizer Canada, Canada
  • Melissa  Hunt, MSc
    Melissa Hunt, MSc Director
    Health Canada, Canada
  • Yatika  Kohli, PhD, MBA
    Yatika Kohli, PhD, MBA Chief Regulatory and Strategy Officer
    NoNO Inc, Canada
  • Rania  Mouchantaf, PhD
    Rania Mouchantaf, PhD A/Executive Director, Marketed Pharmaceuticals Bureau, MHPD
    Health Canada, Canada
  • Kristin  Willemsen, MS
    Kristin Willemsen, MS Vice President, Scientific & Regulatory Affairs
    Food, Health & Consumer Products of Canada, Canada

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。